Immuno-Oncology

HUB

non-CME

Melanoma SLN is Positive, Now What? Debate: Surveillance vs. Adjuvant Immune Checkpoint Blockade for Stage 3a/b Melanoma

HUB Moderator(s)

• 

  Michael Alvarado, MD (he/him/his)

  Professor of Clinical Surgery
  UCSF Helen Diller Family Comprehensive Cancer Center
  San Francisco, California, United States

  Disclosure information not submitted.

Prior to the post-MSLT2 era, the treatment of a microscopically positive SLN was completion lymph node dissection. It is currently accepted that melanoma-specific survival is equivalent between CLND and surveillance. Simultaneously, a growing body of data supports improved outcomes for patients with node positive disease after receipt of adjuvant immunotherapy. It is imperative that surgeons participate in treatment decisions for their patients with positive SLN, and contribute to the research that is shaping this field. The purpose of this session is to understand the current data and provide guidance on how treat patients with positive SLN.

Presentations:

• 9:47am – 9:57am ET

  Surveillance
  

  HUB Presenter: Jonathan S. Zager, MD – H. Lee Moffitt Cancer Center and Research Institute
• 9:57am – 10:07am ET

  Immune Checkpoint Blockade
  

  HUB Presenter: Amanda R. Kirane, MD, PhD (she/her/hers) – Stanford University
• 10:07am – 10:15am ET

  Questions and Discussion